Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Glioma 3Brain Neoplasms 3Oligodendroglioma 2Glioblastoma 2Astrocytoma 2Neoplasms 1Gliosarcoma 1

Interventions

Temozolomide 115Radiotherapy 63Magnetic Resonance Spectroscopy 30Carboplatin 30Bevacizumab 30Carmustine 28Filgrastim 23Surgical Procedures, Operative 22Irinotecan 22Radiation 18Lomustine 17Vincristine 15Etoposide 15Specimen Handling 13Peripheral Blood Stem Cell Transplantation 13O(6)-benzylguanine 13Radiotherapy, Intensity-Modulated 12Procarbazine 11Erlotinib Hydrochloride 11Cyclophosphamide 11Chemotherapy, Adjuvant 11sargramostim 10Thiotepa 10Cisplatin 10Flucytosine 9Everolimus 9antineoplaston AS 2-1 8antineoplaston A10 8Granulocyte Colony-Stimulating Factor 8Vorinostat 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Astrocytoma × perifosine × CNS × Clear all
NCT02238496 2023-05-25

Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas

Columbia University

Phase 1 Completed
10 enrolled
CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma

NCT01051557 2021-07-19

Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma

National Cancer Institute (NCI)

Phase 1/2 Completed
36 enrolled 15 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡